A Randomised trial of the effect and cost-effectiveness of early intensive mulitfactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diaberes:the anglod-Danish-Dutch Study of intensive Treatment in People with Screen-Detected Diabetes in Primary care (ADDITION-Europe) study. (n.d.). http://www.journalslibrary.nihr.ac.uk/hta/volume-20/issue-64#abstract
Amori, R. E., Lau, J., & Pittas, A. G. (2007). Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. JAMA, 298(2). https://doi.org/10.1001/jama.298.2.194
Amy Kennedy. (2013). Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. PLoS ONE, 8(3). https://doi.org/doi: 10.1371/journal.pone.0058861
Anthony H. Barnett, Jenny Grice. (2013). New Mechanisms in Glucose Control. BMJ Books; 1 edition. http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133
[ARCHIVED CONTENT] Medicines management: Everybody’s business : Department of Health - Publications and statistics. (n.d.). http://webarchive.nationalarchives.gov.uk/20080205132320/http:/dh.gov.uk/en/publicationsandstatistics/publications/publicationspolicyandguidance/dh_082200
Atkinson, M. A. (2012). The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine, 2(11), a007641–a007641. https://doi.org/10.1101/cshperspect.a007641
Avery, L., Flynn, D., van Wersch, A., Sniehotta, F. F., & Trenell, M. I. (2012). Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. Diabetes Care, 35(12), 2681–2689. https://doi.org/10.2337/dc11-2452
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010). Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. The Lancet, 375(9733), 2223–2233. https://doi.org/10.1016/S0140-6736(10)60407-2
Bailey, Stephen. (n.d.). Academic Writing : A Handbook for International Students. http://lib.myilibrary.com.ezproxy4.lib.le.ac.uk/Open.aspx?id=310467
Barry, V. W., Baruth, M., Beets, M. W., Durstine, J. L., Liu, J., & Blair, S. N. (2014). Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. Progress in Cardiovascular Diseases, 56(4), 382–390. https://doi.org/10.1016/j.pcad.2013.09.002
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., Nicholson, W. K., Hutfless, S., Bass, E. B., & Bolen, S. (2011). Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. Annals of Internal Medicine, 154(9). https://doi.org/10.7326/0003-4819-154-9-201105030-00336
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., Willi, S. M., & Wood, M. A. (2010). Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal of Medicine, 363(4), 311–320. https://doi.org/10.1056/NEJMoa1002853
Bethel, M. A., Engel, S. S., Green, J. B., Huang, Z., Josse, R. G., Kaufman, K. D., Standl, E., Suryawanshi, S., Van de Werf, F., McGuire, D. K., Peterson, E. D., & Holman, R. R. (2017). Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care, 40(4), 494–501. https://doi.org/10.2337/dc16-1135
Beverley M Shields. (2015). Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open, 5(11). https://doi.org/doi: 10.1136/bmjopen-2015-009088
Birkeland, K. I. (2015). Hyperglycaemia in pregnancy: still a lot to learn. The Lancet Diabetes & Endocrinology, 3(10), 752–753. https://doi.org/10.1016/S2213-8587(15)00282-X
Brown, J., Alwan, N. A., West, J., Brown, S., McKinlay, C. J., Farrar, D., & Crowther, C. A. (1996). Lifestyle interventions for the treatment of women with gestational diabetes. In Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD011970.pub2
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011). Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes. Annals of Internal Medicine, 154(2). https://doi.org/10.7326/0003-4819-154-2-201101180-00300
Buse, J. B., Drucker, D. J., Taylor, K. L., Kim, T., Walsh, B., Hu, H., Wilhelm, K., Trautmann, M., Shen, L. Z., & Porter, L. E. (2010). DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care, 33(6), 1255–1261. https://doi.org/10.2337/dc09-1914
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet, 374(9683), 39–47. https://doi.org/10.1016/S0140-6736(09)60659-0
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | 1-Recommendations | Guidance and guidelines | NICE. (n.d.). https://www.nice.org.uk/guidance/ta390/chapter/1-Recommendations
Capehorn, M., Polonsky, W. H., Edelman, S., Belton, A., Down, S., Gamerman, V., Nagel, F., Lee, J., & Alzaid, A. (2017). Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia ). Diabetic Medicine. https://doi.org/10.1111/dme.13357
Chimen, M., Kennedy, A., Nirantharakumar, K., Pang, T. T., Andrews, R., & Narendran, P. (2012). What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia, 55(3), 542–551. https://doi.org/10.1007/s00125-011-2403-2
Choudhary, P., Parrott, N. R., Birtles, L., & Rutter, M. K. (2012). Islet cell transplantation: current status in the UK (2012). Practical Diabetes, 29(7), 280–285. https://doi.org/10.1002/pdi.1707
Constructs of depression and distress in diabetes: time for an appraisal- ClinicalKey. (n.d.). https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review) TA151, July 2008. (n.d.). http://www.nice.org.uk/guidance/ta151
Copeland, K. C., Silverstein, J., Moore, K. R., Prazar, G. E., Raymer, T., Shiffman, R. N., Springer, S. C., Thaker, V. V., Anderson, M., Spann, S. J., & Flinn, S. K. (2013). Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. PEDIATRICS, 131(2), 364–382. https://doi.org/10.1542/peds.2012-3494
Courtney, H., Nayar, R., Rajeswaran, C., & Jandhyala, R. (2017). Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume 10, 79–87. https://doi.org/10.2147/DMSO.S126763
Creme, P., & Lea, M. R. (2008). Writing At University: A Guide For Students (3rd ed). McGraw-Hill Education. https://ebookcentral.proquest.com/lib/leicester/detail.action?pq-origsite=primo&docID=345134
Dapagliflozin in combination therapy for treating type 2 diabetes June 2013. (n.d.). http://www.nice.org.uk/guidance/ta288
Davies, M., Dahl, D., Heise, T., Kiljanski, J., & Mathieu, C. (2017). Introduction of biosimilar insulins in Europe. Diabetic Medicine, 34(10), 1340–1353. https://doi.org/10.1111/dme.13400
Davies, M. J., Heller, S., Skinner, T. C., Campbell, M. J., Carey, M. E., Cradock, S., Dallosso, H. M., Daly, H., Doherty, Y., Eaton, S., Fox, C., Oliver, L., Rantell, K., Rayman, G., & Khunti, K. (2008). Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ, 336(7642), 491–495. https://doi.org/10.1136/bmj.39474.922025.BE
Dhatariya, K. K., Skedgel, C., & Fordham, R. (2017). The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. Diabetic Medicine, 34(10), 1361–1366. https://doi.org/10.1111/dme.13427
Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3. (n.d.). https://www.nice.org.uk/guidance/ng3
Diagnosis and management of type 1 diabetes in children, young people and adults | Guidance and guidelines | NICE. (n.d.). https://www.nice.org.uk/guidance/cg15
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010). Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet, 375(9733), 2234–2243. https://doi.org/10.1016/S0140-6736(10)60406-0
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014). Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. The Lancet, 384(9951), 1349–1357. https://doi.org/10.1016/S0140-6736(14)60976-4
Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis. (n.d.). http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. (2016). New England Journal of Medicine, 375(18), 1799–1802. https://doi.org/10.1056/NEJMc1611290
Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes | Guidance and guidelines TA 248 Feb 2015. (n.d.). https://www.nice.org.uk/guidance/ta248
Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. (n.d.). Journal of Diabetes Science and Technology (Online), 3(4). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/
Fagin, J. A., & Wells, S. A. (2016). Biologic and Clinical Perspectives on Thyroid Cancer. New England Journal of Medicine, 375(11), 1054–1067. https://doi.org/10.1056/NEJMra1501993
Ferrari, M., Dal Cin, M., & Steele, M. (2017). Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes. Diabetic Medicine, 34(11), 1546–1553. https://doi.org/10.1111/dme.13451
Gale, E. A. (2013). Is type 2 diabetes a category error? The Lancet, 381(9881), 1956–1957. https://doi.org/10.1016/S0140-6736(12)62207-7
Gallwitz, B., Rosenstock, J., Rauch, T., Bhattacharya, S., Patel, S., von Eynatten, M., Dugi, K. A., & Woerle, H.-J. (2012). 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. The Lancet, 380(9840), 475–483. https://doi.org/10.1016/S0140-6736(12)60691-6
Grammes, J., Stock, W., Mann, C. G., Flynn, E. M., & Kubiak, T. (2017). Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. Diabetic Medicine. https://doi.org/10.1111/dme.13506
Gray, L. J., Khunti, K., Edwardson, C., Goldby, S., Henson, J., Morris, D. H., Sheppard, D., Webb, D., Williams, S., Yates, T., & Davies, M. J. (2012). Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. Diabetologia, 55(12), 3238–3244. https://doi.org/10.1007/s00125-012-2725-8
Gray, L. J., Khunti, K., Wilmot, E. G., Yates, T., & Davies, M. J. (2014). External validation of two diabetes risk scores in a young UK South Asian population. Diabetes Research and Clinical Practice, 104(3), 451–458. https://doi.org/10.1016/j.diabres.2014.03.018
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., Lachin, J. M., McGuire, D. K., Pencina, M. J., Standl, E., Stein, P. P., Suryawanshi, S., Van de Werf, F., Peterson, E. D., & Holman, R. R. (2015). Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 373(3), 232–242. https://doi.org/10.1056/NEJMoa1501352
Gregg, E. W. (2017). The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016. Diabetes Care. https://doi.org/10.2337/dci16-0055
Guidelines. (n.d.). https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes
Hadjiconstantinou, M., Byrne, J., Bodicoat, D. H., Robertson, N., Eborall, H., Khunti, K., & Davies, M. J. (2016). Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 18(10). https://doi.org/10.2196/jmir.5991
Harman-Boehm, I. (2008). Continuous glucose monitoring in type 2 diabetes. Diabetes Research and Clinical Practice, 82, S118–S121. https://doi.org/10.1016/j.diabres.2008.09.051
Hartman, Y. A. W., Jansen, H. J., Hopman, M. T. E., Tack, C. J., & Thijssen, D. H. J. (2017). Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. Diabetes Care, 40(9), e120–e121. https://doi.org/10.2337/dc17-0787
Heinonen, I., Helajärvi, H., Pahkala, K., Heinonen, O. J., Hirvensalo, M., Pälve, K., Tammelin, T., Yang, X., Juonala, M., Mikkilä, V., Kähönen, M., Lehtimäki, T., Viikari, J., & Raitakari, O. T. (2013). Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. BMJ Open, 3(6). https://doi.org/10.1136/bmjopen-2013-002901
Henson, Joseph. (2014). Associations of Sedentary Time with Fat Distribution in a High-Risk Population. https://lra.le.ac.uk/handle/2381/32505
Hessler, D. M., Fisher, L., Polonsky, W. H., Masharani, U., Strycker, L. A., Peters, A. L., Blumer, I., & Bowyer, V. (2017). Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. Diabetic Medicine, 34(9), 1228–1234. https://doi.org/10.1111/dme.13381
Holt, R. I. G. (2010a). Textbook of diabetes (4th ed). Wiley-Blackwell. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
Holt, R. I. G. (2010b). Textbook of diabetes (4th ed). Wiley-Blackwell. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
Holt, R. I. G. (2010c). Textbook of diabetes (4th ed). Wiley-Blackwell. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
Holt, R. I. G. (2010d). Textbook of diabetes (4th ed). Wiley-Blackwell. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
Holt, R. I. G. (2010e). Textbook of diabetes (4th ed). Wiley-Blackwell. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
Holt, R. I. G. (2010f). Textbook of diabetes (4th ed). Wiley-Blackwell. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
Holt, R. I. G. (2010g). Textbook of diabetes (4th ed). Wiley-Blackwell. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
Holt, R. I. G. (2010h). Textbook of diabetes (4th ed). Wiley-Blackwell. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
Holt, R. I. G. (2010i). Textbook of diabetes (4th ed). Wiley-Blackwell. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
Holt, R. I. G. (2010j). Textbook of diabetes (4th ed). Wiley-Blackwell. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016a). Textbook of Diabetes (5th ed). John Wiley & Sons, Incorporated. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016b). Textbook of Diabetes (5th ed). John Wiley & Sons, Incorporated. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016c). Textbook of Diabetes (5th ed). John Wiley & Sons, Incorporated. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016d). Textbook of Diabetes (5th ed). John Wiley & Sons, Incorporated. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016e). Textbook of Diabetes (5th ed). John Wiley & Sons, Incorporated. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016f). Textbook of Diabetes (5th ed). John Wiley & Sons, Incorporated. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016g). Textbook of Diabetes (5th ed). John Wiley & Sons, Incorporated. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016h). Textbook of Diabetes (5th ed). John Wiley & Sons, Incorporated. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016i). Textbook of Diabetes (5th ed). John Wiley & Sons, Incorporated. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015). Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 38(1), 140–149. https://doi.org/10.2337/dc14-2441
Jelinek, H. F., Stranieri, A., Yatsko, A., & Venkatraman, S. (2016). Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. Computers in Biology and Medicine, 75, 90–97. https://doi.org/10.1016/j.compbiomed.2016.05.005
John M Jakicic. (2005). Physical activity considerations for the treatment and prevention of obesity. The American Journal of Clinical Nutrition, 82(1), 226S-229S. http://ajcn.nutrition.org/content/82/1/226S
Johnston, B. C., Kanters, S., Bandayrel, K., Wu, P., Naji, F., Siemieniuk, R. A., Ball, G. D. C., Busse, J. W., Thorlund, K., Guyatt, G., Jansen, J. P., & Mills, E. J. (2014). Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. JAMA, 312(9). https://doi.org/10.1001/jama.2014.10397
Jones, A. G., & Hattersley, A. T. (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine, 30(7), 803–817. https://doi.org/10.1111/dme.12159
Kamlesh Khunti. (2015). Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. PLoS ONE, 10(9). https://doi.org/doi: 10.1371/journal.pone.0135702
Kenneth Hodson. (2010). Gestational diabetes: emerging concepts in pathophysiology. Obstetric Medicine, 3(4). https://doi.org/doi: 10.1258/om.2010.100025
Latika Sahu. (2009). Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. Obstetric Medicine, 2(4). https://doi.org/doi: 10.1258/om.2009.080049
Lee, I.-M. (2010). Physical Activity and Weight Gain Prevention. JAMA, 303(12). https://doi.org/10.1001/jama.2010.312
Leelarathna, L., Roberts, S. A., Hindle, A., Markakis, K., Alam, T., Chapman, A., Morris, J., Urwin, A., Jinadev, P., & Rutter, M. K. (2017). Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. Diabetic Medicine, 34(10), 1372–1379. https://doi.org/10.1111/dme.13412
Leff, D. R., & Heath, D. (2009). Surgery for obesity in adulthood. BMJ, 339(sep22 1), b3402–b3402. https://doi.org/10.1136/bmj.b3402
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017). Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume 10, 123–139. https://doi.org/10.2147/DMSO.S130834
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. (2016). New England Journal of Medicine, 375(18), 1797–1799. https://doi.org/10.1056/NEJMc1611289
Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010. (n.d.-a). https://www.nice.org.uk/guidance/ta203
Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010. (n.d.-b). https://www.nice.org.uk/guidance/ta203
Managing Older People with Type 2 Diabetes: IDF Global Guideline - International Federation on Ageing. (n.d.). https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1607141
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016a). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016b). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827
Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. CG76, Jan 2009. (n.d.). https://www.nice.org.uk/guidance/cg76
Merlin C. Thomas. (2016). Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. Diabetes Therapy, 7(3). https://doi.org/doi: 10.1007/s13300-016-0189-4
Min, S. H., Yoon, J.-H., Hahn, S., & Cho, Y. M. (2017). Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes/Metabolism Research and Reviews, 33(1). https://doi.org/10.1002/dmrr.2818
Minimizing Hypoglycemia in Diabetes: Table 1. (2015). Diabetes Care, 38(8), 1583–1591. https://doi.org/10.2337/dc15-0279
Mishriky, B. M., Cummings, D. M., & Tanenberg, R. J. (2015). The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 109(2), 378–388. https://doi.org/10.1016/j.diabres.2015.05.025
Moreno-Castilla, C., Mauricio, D., & Hernandez, M. (2016). Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. Current Diabetes Reports, 16(4). https://doi.org/10.1007/s11892-016-0717-7
Narendran, P., Jackson, N., Daley, A., Thompson, D., Stokes, K., Greenfield, S., Charlton, M., Curran, M., Solomon, T. P. J., Nouwen, A., Lee, S. I., Cooper, A. R., Mostazir, M., Taylor, R. S., Kennedy, A., & Andrews, R. C. (2017). Exercise to preserve β-cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial. Diabetic Medicine, 34(11), 1521–1531. https://doi.org/10.1111/dme.13439
National Obesity Observatory. (n.d.). http://www.noo.org.uk
Nauck, M. A., & Meier, J. J. (2016). The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. The Lancet Diabetes & Endocrinology, 4(6), 525–536. https://doi.org/10.1016/S2213-8587(15)00482-9
Nauck, M. A., Meininger, G., Sheng, D., Terranella, L., & Stein, P. P. (2007). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism, 9(2), 194–205. https://doi.org/10.1111/j.1463-1326.2006.00704.x
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014). Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care, 37(8), 2149–2158. https://doi.org/10.2337/dc13-2761
NHS Evidence: an introduction. (n.d.). http://www.solent.nhs.uk/_store/documents/nhs_evidence_guide.pdf
Nissen, S. E., & Wolski, K. (2007). Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. New England Journal of Medicine, 356(24), 2457–2471. https://doi.org/10.1056/NEJMoa072761
Noctor, E., & Dunne, F. (2015). Postnatal testing following gestational diabetes. The Lancet Diabetes & Endocrinology, 3(10), 761–762. https://doi.org/10.1016/S2213-8587(15)00322-8
Nolan, C. J., Ruderman, N. B., Kahn, S. E., Pedersen, O., & Prentki, M. (2015). Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes, 64(3), 673–686. https://doi.org/10.2337/db14-0694
Obesity: identification, assessment and management | Guidance and guidelines | NICE. (n.d.). https://www.nice.org.uk/guidance/cg189
Paul Craddy. (2014). Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. Diabetes Therapy, 5(1). https://doi.org/doi: 10.1007/s13300-014-0061-3
Perrin, N. E., Davies, M. J., Robertson, N., Snoek, F. J., & Khunti, K. (2017). The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. Diabetic Medicine, 34(11), 1508–1520. https://doi.org/10.1111/dme.13448
Persaud, S. J., & Jones, P. M. (2016). A Wake-up Call for Type 2 Diabetes? New England Journal of Medicine, 375(11), 1090–1092. https://doi.org/10.1056/NEJMcibr1607950
Pickup, J. C. (2012). Insulin-Pump Therapy for Type 1 Diabetes Mellitus. New England Journal of Medicine, 366(17), 1616–1624. https://doi.org/10.1056/NEJMct1113948
Qin, L., Knol, M. J., Corpeleijn, E., & Stolk, R. P. (2010). Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. European Journal of Epidemiology, 25(1), 5–12. https://doi.org/10.1007/s10654-009-9395-y
Rasouli, B., Andersson, T., Carlsson, P.-O., Hjort, R., Löfvenborg, J. E., Martinell, M., Groop, L., Tuomi, T., & Carlsson, S. (2017). Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes. Diabetic Medicine, 34(9), 1259–1263. https://doi.org/10.1111/dme.13410
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013). Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care, 36(9), 2489–2496. https://doi.org/10.2337/dc12-2454
Rinki Murphy. (2015). Monogenic diabetes and pregnancy. Obstetric Medicine, 8(3). https://doi.org/doi: 10.1177/1753495X15590713
Rizos, C. V., Kei, A., & Elisaf, M. S. (2016). The current role of thiazolidinediones in diabetes management. Archives of Toxicology, 90(8), 1861–1881. https://doi.org/10.1007/s00204-016-1737-4
Rotz, M. E., Ganetsky, V. S., Sen, S., & Thomas, T. F. (2015). Implications of incretin-based therapies on cardiovascular disease. International Journal of Clinical Practice, 69(5), 531–549. https://doi.org/10.1111/ijcp.12572
Ryder, B., McKnight, J., Blann, A., Dhatariya, K., Gregory, R., Robinson, T., Rowles, S., Sharp, P., Winocour, P. H., & Walton, C. (2013). ABCD position statement on GLP-1 based therapies and pancreatic damage. Practical Diabetes, 30(9), 388–391. https://doi.org/10.1002/pdi.1816
S M Attard. (2015). Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. Nutrition & Diabetes, 5(6). https://doi.org/doi: 10.1038/nutd.2015.16
Sallis, J. F., Bull, F., Guthold, R., Heath, G. W., Inoue, S., Kelly, P., Oyeyemi, A. L., Perez, L. G., Richards, J., & Hallal, P. C. (2016). Progress in physical activity over the Olympic quadrennium. The Lancet, 388(10051), 1325–1336. https://doi.org/10.1016/S0140-6736(16)30581-5
Samuel, V. T., & Shulman, G. I. (2012). Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell, 148(5), 852–871. https://doi.org/10.1016/j.cell.2012.02.017
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., & Kashyap, S. R. (2017a). Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. New England Journal of Medicine, 376(7), 641–651. https://doi.org/10.1056/NEJMoa1600869
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., & Kashyap, S. R. (2017b). Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. New England Journal of Medicine, 376(7), 641–651. https://doi.org/10.1056/NEJMoa1600869
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012). Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. New England Journal of Medicine, 366(17), 1567–1576. https://doi.org/10.1056/NEJMoa1200225
Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B. (2016). The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema. Diabetes Care, 39(2), 179–186. https://doi.org/10.2337/dc15-1585
Sivasubramaniyam, S., Amiel, S. A., & Choudhary, P. (2017). Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. Diabetic Medicine, 34(10), 1456–1460. https://doi.org/10.1111/dme.13438
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., Sullivan, M., & Wedel, H. (2004). Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. New England Journal of Medicine, 351(26), 2683–2693. https://doi.org/10.1056/NEJMoa035622
Srinivasan, P., Huang, G. C., Amiel, S. A., & Heaton, N. D. (2007). Islet cell transplantation. Postgraduate Medical Journal, 83(978), 224–229. https://doi.org/10.1136/pgmj.2006.053447
Standards of Medical Care in Diabetes--2015: Summary of Revisions. (2015). Diabetes Care, 38(Supplement_1), S4–S4. https://doi.org/10.2337/dc15-S003
Steven, S., Hollingsworth, K. G., Al-Mrabeh, A., Avery, L., Aribisala, B., Caslake, M., & Taylor, R. (2016). Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. Diabetes Care, 39(5), 808–815. https://doi.org/10.2337/dc15-1942
Steven, S., & Taylor, R. (2015). Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. Diabetic Medicine, 32(9), 1149–1155. https://doi.org/10.1111/dme.12722
Stewart, Z. A., Wilinska, M. E., Hartnell, S., Temple, R. C., Rayman, G., Stanley, K. P., Simmons, D., Law, G. R., Scott, E. M., Hovorka, R., & Murphy, H. R. (2016). Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. New England Journal of Medicine, 375(7), 644–654. https://doi.org/10.1056/NEJMoa1602494
Tanner, M. (2016). Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. Annals of Internal Medicine, 165(4). https://doi.org/10.7326/ACPJC-2016-165-4-020
Tao, L., Wilson, E. C. F., Wareham, N. J., Sandbaek, A., Rutten, G. E. H. M., Lauritzen, T., Khunti, K., Davies, M. J., Borch-Johnsen, K., Griffin, S. J., & Simmons, R. K. (2015). Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabetic Medicine, 32(7), 907–919. https://doi.org/10.1111/dme.12711
The Eatwell Guide. (2016). Public Health England. https://www.gov.uk/government/publications/the-eatwell-guide
Type 2 diabetes in adults: management | Guidance and guidelines | NICE. (n.d.). https://www.nice.org.uk/guidance/ng28
Type 2 diabetes: lixisenatide | Evidence-review | Advice | NICE. (n.d.). https://www.nice.org.uk/advice/esnm26/chapter/evidence-review
Type 2 diabetes: prevention in people at high risk | Guidance and guidelines | NICE. (n.d.). http://www.nice.org.uk/guidance/PH38
Umpierre, D. (2011). Physical Activity Advice Only or Structured Exercise Training and Association With HbA Levels in Type 2 Diabetes. JAMA, 305(17). https://doi.org/10.1001/jama.2011.576
Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care. (n.d.). http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview
Villani, M., de Courten, B., & Zoungas, S. (2017). Emergency treatment of hypoglycaemia: a guideline and evidence review. Diabetic Medicine, 34(9), 1205–1211. https://doi.org/10.1111/dme.13379
Vloemans, A. F., van Beers, C. A. J., de Wit, M., Cleijne, W., Rondags, S. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Serné, E. H., & Snoek, F. J. (2017). Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. Diabetic Medicine, 34(10), 1470–1476. https://doi.org/10.1111/dme.13429
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016). Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine, 375(4), 323–334. https://doi.org/10.1056/NEJMoa1515920
William H. Polonsky,Lawrence Fisher,Jay Earles,R. James Dudl,Joel Lees,Joseph Mullan. (n.d.). Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. Diabetes Care. http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=25&docId=GALE%7CA130282980&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA130282980&searchId=R15&userGroupName=leicester&inPS=true
Yates, T., & Davies, M. J. (2017). Physical activity and Type 1 diabetes: an underused therapy. Diabetic Medicine, 34(11), 1498–1499. https://doi.org/10.1111/dme.13445
Yeh, J. S., Kushner, R. F., & Schiff, G. D. (2016). Obesity and Management of Weight Loss. New England Journal of Medicine, 375(12), 1187–1189. https://doi.org/10.1056/NEJMclde1515935
Young-Hyman, D., de Groot, M., Hill-Briggs, F., Gonzalez, J. S., Hood, K., & Peyrot, M. (2017). Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140. Diabetes Care, 40(2), 287.1-287. https://doi.org/10.2337/dc17-er02
Zaccardi, F., Webb, D. R., Yates, T., & Davies, M. J. (2016). Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgraduate Medical Journal, 92(1084), 63–69. https://doi.org/10.1136/postgradmedj-2015-133281
